Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$108.19 USD

108.19
1,486,096

+2.19 (2.07%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $108.20 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Lam Research (LRCX) to Post Q3 Earnings: What's in the Cards?

Lam Research's (LRCX) third-quarter fiscal 2024 results are expected to reflect strength in 3D DRAM and advanced packaging amid a slowdown in memory spending.

GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging

GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

Intuitive Surgical (ISRG) Q1 Earnings Beat, Procedures Robust

Intuitive Surgical's (ISRG) first-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

What's in Store for Texas Instruments (TXN) in Q1 Earnings?

Texas Instruments' (TXN) first-quarter 2024 results are likely to reflect the adverse impacts of inventory reduction and macro headwinds.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.

Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay

Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.

GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imaging

GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.

Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up

Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.

What's in Store for Taiwan Semiconductors' (TSM) Q1 Earnings?

Taiwan Semiconductor's (TSM) first-quarter 2024 results are expected to reflect gains from its robust technology portfolio amid headwinds.

What's in the Offing for ASML Holding's (ASML) Q1 Earnings?

ASML Holding's (ASML) first-quarter results are expected to reflect the benefits of strong momentum across the EUV and DUV systems amid macroeconomic headwinds.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Philips (PHG) Agrees to a Consent Decree With DOJ and FDA

Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.

Cardinal Health (CAH) Increases Despite Market Slip: Here's What You Need to Know

In the latest trading session, Cardinal Health (CAH) closed at $107.03, marking a +1.84% move from the previous day.

GE HealthCare (GEHC) to Showcase Enhanced Breast Cancer Imaging

GE HealthCare's (GEHC) latest breast cancer detection technology is likely to enhance the detection and diagnosis of breast cancer and improve patient outcomes.

DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management

DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing

QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.

Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio

Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.

Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail

Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.

Reasons to Hold The Cooper Companies (COO) in Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?

Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.